Vaxart Inc. Faces Delisting from Nasdaq Due to Noncompliance with Listing Requirements

Reuters09-23

Vaxart Inc. Faces Delisting from Nasdaq Due to Noncompliance with Listing Requirements

Vaxart Inc. has announced a regulatory issue concerning its continued listing on the Nasdaq Stock Market. The company had previously been granted a conditional extension by the Nasdaq Hearings Panel to maintain its listing, contingent upon receiving shareholder approval for a reverse stock split and meeting Nasdaq's minimum bid price requirement. However, Vaxart withdrew its proposal for the reverse stock split before the scheduled special meeting of stockholders. Consequently, on September 19, 2025, Vaxart received a letter from Nasdaq's General Counsel notifying the company that its securities will be delisted due to noncompliance with the set conditions. Trading of Vaxart's common stock on Nasdaq had already been suspended as of July 8, 2025, and the stock is now quoted on the OTCQX® Best Market under the symbol "VXRT."

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxart Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-029485), on September 19, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2569771188?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-23 23:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569771188","market":"fut","top_or_hot":-1,"title":"Vaxart Inc. Faces Delisting from Nasdaq Due to Noncompliance with Listing Requirements","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vaxart Inc. Faces Delisting from Nasdaq Due to Noncompliance with Listing Requirements\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vaxart Inc. has announced a regulatory issue concerning its continued listing on the Nasdaq Stock Market. The company had previously been granted a conditional extension by the Nasdaq Hearings Panel to maintain its listing, contingent upon receiving shareholder approval for a reverse stock split and meeting Nasdaq's minimum bid price requirement. However, Vaxart withdrew its proposal for the reverse stock split before the scheduled special meeting of stockholders. Consequently, on September 19, 2025, Vaxart received a letter from Nasdaq's General Counsel notifying the company that its securities will be delisted due to noncompliance with the set conditions. Trading of Vaxart's common stock on Nasdaq had already been suspended as of July 8, 2025, and the stock is now quoted on the OTCQX® Best Market under the symbol \"VXRT.\"\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxart Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-029485), on September 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart Inc. Faces Delisting from Nasdaq Due to Noncompliance with Listing Requirements</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart Inc. Faces Delisting from Nasdaq Due to Noncompliance with Listing Requirements\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-23 23:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vaxart Inc. Faces Delisting from Nasdaq Due to Noncompliance with Listing Requirements\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vaxart Inc. has announced a regulatory issue concerning its continued listing on the Nasdaq Stock Market. The company had previously been granted a conditional extension by the Nasdaq Hearings Panel to maintain its listing, contingent upon receiving shareholder approval for a reverse stock split and meeting Nasdaq's minimum bid price requirement. However, Vaxart withdrew its proposal for the reverse stock split before the scheduled special meeting of stockholders. Consequently, on September 19, 2025, Vaxart received a letter from Nasdaq's General Counsel notifying the company that its securities will be delisted due to noncompliance with the set conditions. Trading of Vaxart's common stock on Nasdaq had already been suspended as of July 8, 2025, and the stock is now quoted on the OTCQX® Best Market under the symbol \"VXRT.\"\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxart Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-029485), on September 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VXRT","symbol_name":"Vaxart, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nNDL52z3lZ:1","article_id":"2569771188","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569771188","pubTimestamp":1758640734,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Vaxart Inc. has announced a regulatory issue concerning its continued listing on the Nasdaq Stock Market. The company had previously been granted a conditional extension by the Nasdaq Hearings Panel to maintain its listing, contingent upon receiving shareholder approval for a reverse stock split and meeting Nasdaq's minimum bid price requirement. However, Vaxart withdrew its proposal for the reverse stock split before the scheduled special meeting of stockholders. Consequently, on September 19, 2025, Vaxart received a letter from Nasdaq's General Counsel notifying the company that its securities will be delisted due to noncompliance with the set conditions. Trading of Vaxart's common stock on Nasdaq had already been suspended as of July 8, 2025, and the stock is now quoted on the OTCQX Best Market under the symbol \"VXRT.\"","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VXRT":"Vaxart, Inc.","BK4568":"美国抗疫概念","BK4139":"生物科技"},"translate_title":"Vaxart Inc.因不遵守上市要求面临从纳斯达克退市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXRT":0.9},"content_text":"Vaxart Inc. Faces Delisting from Nasdaq Due to Noncompliance with Listing Requirements\n    \n\n        Vaxart Inc. has announced a regulatory issue concerning its continued listing on the Nasdaq Stock Market. The company had previously been granted a conditional extension by the Nasdaq Hearings Panel to maintain its listing, contingent upon receiving shareholder approval for a reverse stock split and meeting Nasdaq's minimum bid price requirement. However, Vaxart withdrew its proposal for the reverse stock split before the scheduled special meeting of stockholders. Consequently, on September 19, 2025, Vaxart received a letter from Nasdaq's General Counsel notifying the company that its securities will be delisted due to noncompliance with the set conditions. Trading of Vaxart's common stock on Nasdaq had already been suspended as of July 8, 2025, and the stock is now quoted on the OTCQX® Best Market under the symbol \"VXRT.\"\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxart Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-029485), on September 19, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2569771188","isCrawlerRequest":true}